ZVRA Stock Analysis: Buy, Sell, or Hold?
ZVRA - Zevra Therapeutics, Inc. Common Stock
$10.06
0.54 (5.73%)
▲
5d:
+3.55%
30d:
-28.08%
90d:
-0.15%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
TODAY
Get Alerted When ZVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ZVRA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: ZVRA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$8.20
Based on -5.2% avg growth
INTRINSIC VALUE TODAY
$5.09
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZVRA is currently trading at $10.05, which is considered oversold relative to its 30-day fair value range of $10.68 to $14.15. The stock's valuation (Forward PE: 9.5) is in line with its historical norms (10.3). Remarkably, the market is currently pricing in an annual earnings decline of 2.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZVRA is in a strong uptrend. Immediate support is located at $9.10, while resistance sits at $12.56. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $25.00 (+148.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZVRA is in a strong uptrend. Immediate support is located at $9.10, while resistance sits at $12.56. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $25.00 (+148.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.68 -
$14.15
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.7%)
- BULLISH: Trading 148.6% below Wall St target ($25.00)
Trading Range Analysis
30-Day Trading Range
$10.68 -
$14.15
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.10
Resistance Level
$12.56
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.53
Wall Street Target
$25.00
(+148.6%)
Revenue Growth (YoY)
77.5%
Profit Margin
101.6%
Valuation Discount vs History
-2.5% cheaper
PE vs Historical
9.5 vs 10.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.5%
(market-implied from PE analysis)
1-Year Target
$9.80
(-3%)
2-Year Target
$9.56
(-5%)
3-Year Target
$9.32
(-7%)
3-Yr Target (if PE normalizes)
(PE: 10→10)
$10.07
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: -14.5%)
$15.94
(+59%)
Base:
(SPY PE: 9.5, Growth: -14.5%)
$7.33
(-27%)
Bear:
(PE: 8.1, Growth: -14.5%)
$6.23
(-38%)
📈
Valuation based on Current Earnings
Trailing PE: 4.73 | Current EPS (TTM): $2.01
Bull Case
$5.49
(-45%)
Analyst growth -47.5%, PE expands to 5.2
Base Case
$4.99
(-50%)
Market implied -47.5%, PE stable at 4.7
Bear Case
$6.47
(-36%)
Severe decline -20.0%, PE contracts to 4.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.5 to 10.3
Stabilization Target:
$10.87
(+8.1%)
PE Expansion Potential:
+8.1%
Share & Embed Analysis
Last updated: August 04, 2026 5:13 AM ET
Data refreshes hourly during market hours. Next update: 6:13 AM
Data refreshes hourly during market hours. Next update: 6:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 59 HOLD |
Advanced ZVRA Option Strategies
Professional options setups generated by AI based on today's ZVRA price and gamma walls.
